Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
Epsilogen, a UK-based spinout of King’s College London working on cancer treatments that exploit immunoglobulin E antibodies, pocketed £30.75m ($41.2m) in a series B round backed by commercialisation firm Epidarex Capital yesterday. The round was led by Novartis Venture Fund on behalf of pharmaceutical firm Novartis, and also included Alsa Ventures, 3B Future Health Fund,…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Talking Tech Transfer interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
